Sterling Capital Management’s Neurogene NGNE Stock Holding History

Sterling Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.17K	Sell	228 -146	-39%	-$4.02K	﹤0.01%	2412
2026 Q1	$7.54K	Sell	374 -193	-34%	-$3.74K	﹤0.01%	2521
2025 Q4	$11.7K	Sell	567 -112	-16%	-$2.79K	﹤0.01%	2532
2025 Q3	$11.8K	Buy	679 +413	+155%	+$8.29K	﹤0.01%	2402
2025 Q2	$3.98K	Buy	266 +163	+158%	+$2.56K	﹤0.01%	2632
2025 Q1	$1.21K	Sell	103 -68	-40%	-$1.18K	﹤0.01%	2754
2024 Q4	$3.91K	Buy	171 +149	+677%	+$5.54K	﹤0.01%	2563
2024 Q3	$923	Buy	+22	New	+$853	﹤0.01%	2576
2015 Q2	–	Sell	-650	Closed	-$107K	–	913
2015 Q1	$107K	Hold	650	–	–	﹤0.01%	856
2014 Q4	$97K	Sell	650 -86	-12%	-$12.2K	﹤0.01%	899
2014 Q3	$98K	Hold	736	–	–	﹤0.01%	882
2014 Q2	$139K	Sell	736 -442	-38%	-$85.3K	﹤0.01%	865
2014 Q1	$300K	Buy	+1,178	New	+$303K	﹤0.01%	860

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Sterling Capital Management's NGNE Position: Q2 2026 in Review

Sterling Capital Management reduced its Neurogene (NGNE) stake by 39% in Q2 2026, selling an estimated $4.02K and leaving 228 shares worth $7.17K. The position accounts for ﹤0.01% of the portfolio, ranked #2412.

Sterling Capital Management first reported a position in NGNE in Q1 2014 and has held it in 13 quarters since. The position peaked at $300K in Q1 2014. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

Sterling Capital Management held 228 shares of Neurogene worth $7.17K as of Q2 2026.
Sterling Capital Management sold 146 Neurogene shares in Q2 2026, an estimated $4.02K.
Neurogene made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2412 holding.
Sterling Capital Management first reported a position in Neurogene in Q1 2014 and has held it in 13 quarters since.
Sterling Capital Management's Neurogene position peaked at $300K in Q1 2014.
112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.